Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression
Alto Neuroscience, Inc. (ANRO)
Company Research
Source: Business Wire
— Phase 2b closely resembles PAX-D study design, which demonstrated an effect size for pramipexole more than two times larger than approved TRD therapies —— Trial design and MADRS primary endpoint aligned with FDA standards in depression, potentially supporting a single Phase 3 registrational pathway —— Prior Phase 2a demonstrated robust antidepressant effects of ALTO-207 and favorable tolerability —— Topline data expected in 2H 2027 — MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on precision medicines for neuropsychiatric disorders, today announced the initiation of a Phase 2b randomized, placebo-controlled trial of ALTO-207 in treatment-resistant depression (TRD), a program designed to replicate the strongly positive PAX-D study results and support a streamlined path to registration. TRD is estimated to affect up to 7 million adults in the United States, representing patients who do not respond ad
Show less
Read more
Impact Snapshot
Event Time:
ANRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANRO alerts
High impacting Alto Neuroscience, Inc. news events
Weekly update
A roundup of the hottest topics
ANRO
News
- Alto Neuroscience Starts Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression [Yahoo! Finance]Yahoo! Finance
- Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression [Yahoo! Finance]Yahoo! Finance
- Alto Neuroscience (ANRO) had its price target lowered by Robert W. Baird from $41.00 to $38.00. They now have an "outperform" rating on the stock.MarketBeat
- Alto Neuroscience (ANRO) had its "buy" rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.MarketBeat
- Alto Neuroscience (ANRO) had its price target lowered by JonesTrading from $49.00 to $44.00. They now have a "buy" rating on the stock.MarketBeat
ANRO
Earnings
- 3/16/26 - Miss
ANRO
Sec Filings
- 4/21/26 - Form EFFECT
- 4/10/26 - Form S-3
- 4/1/26 - Form 8-K
- ANRO's page on the SEC website